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New insights into the pathogenesis of Crohn’s
disease: are they relevant for therapeutic
options?
Stephan R. Vavricka, Gerhard Rogler
Division of Gastroenterology and Hepatology, Department of Internal Medicine, University Hospital,
Zurich, Switzerland
During the last few years significant advances
have been achieved in the understanding of the
pathogenesis of inflammatory bowel disease
(IBD). A genetic susceptibility to Crohn’s disease
has been proven by identification of variations as
risk factor NOD2/CARD15. Functional data on
NOD2/CARD15 and NF-κB activation indicate
that an inflammatory reaction of the intestinal
mucosa, as an immediate response of the innate
immune system, may be necessary for the mainte-
nance of gut homeostasis. Crohn’s disease is now
also discussed as an impaired and inadequate im-
mune reaction and no longer only as a hyper-re-
sponsiveness of the mucosal immune system.
Data on NOD2/CARD15 expression suggest that
macrophages and epithelial cells could be the
locus of the primary pathophysiological defect
and that T-cell activation might just be a second-
ary effect inducing chronification of the inflam-
mation, perhaps as backup mechanism to insuffi-
cient innate immunity. In addition to
NOD2/CARD15 there are more “innate” path-
ways by which commensal and pathogenic bacte-
ria can directly be hindered to invade the human
body (such as interaction with Toll like receptors,
TLRs and defensins). The “germ-concept” and
the “genetic concept” of IBD pathophysiology are
converging. However, more time is needed until
these important insights in IBD pathogenesis will
make their way into routine diagnostic proce-
dures and treatment of patients with IBD.
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Susceptibility genes and IBD pathogenesis
Significant progress has been made in recent
years to the field of IBD pathogenesis. A number
of very important new insights have been gained.
Whereas research on IBD pathogenesis used to be
influenced by results from immunology and
rheumatology, new findings in IBD patients stim-
ulate other fields such as investigations on innate
immunity and mucosal barrier functions. Studies
on pathogenesis of Crohn’s disease (CD) have
stimulated research in hematology (graft versus
host disease), transplantation medicine (outcome
of small intestinal transplantation), dentistry (pe-
riodontal disease) or pediatrics (immune deficien-
cies). It can be expected that this progress in the
understanding of IBD pathophysiology will soon
change our therapeutic concepts. Therefore, it
will be important for physicians to know about
those recent advances.
An involvement of genetic factors in CD
pathogenesis had long been postulated. From
twin studies it was evident that more that 50%
concordance of CD in monozygotic twin pairs can
be expected [1, 2]. A recent study again has shown
concordance for CD in 63.6% among
monozygotic twins, however, only 3.6% among
dizygotic twins [3]. These data suggest that the
genetic background is responsible for at least 50%
of the risk or “susceptibility” to develop CD. Ob-
viously, it is not a sufficient condition as otherwise
there would be 100% concordance of disease in
monozygotic twin pairs. On the other hand a ge-
netic risk of 50% seemed to be promising enough
to justify a worldwide search for susceptibility
genes. It soon became obvious that not a single
gene or mutation could account for the complete
susceptibility to develop CD and that the patho-
genesis of CD is based on a polygeneic risk profile
[1, 2].
The proof of the concept was achieved in
2001 with the discovery that NOD2/CARD15 is
the most important susceptibility gene for CD [4–
6]. About 20 to 40% of all patients – depending on
the genetic background – carry variants of this
gene in contrast to 10–15% in the healthy popu-
lation. In the previously mentioned study on
monozygotic twins these relative amounts are
even higher: 44% of patients with CD were posi-
tive for one ore more mutant alleles of
NOD2/CARD15 compared to 2% of UC pa-
tients and 19% of healthy twins [3]. By detailed
analyses of the impact of the NOD2 gene knowl-
edge has been gained about genotype-phenotype
correlations but also about the difficulties in find-
ing an impact of those discoveries for the clinical
management of patients []. Three major NOD2
genetic variants are associated with CD in Cau-
casians in several independent studies. However,
NOD2 variants are irrelevant in the Asian popu-
lation and do not play any role for the pathogene-
sis of CD in Japan or China [8–13].
NOD2 variants explain up to one third of the
genetic susceptibility for CD. Genotype-pheno-
type analyses have demonstrated some association
of NOD2 variants with ileum-specific disease, an
increased incidence of the fibrostenotic pheno-
type and an earlier age of disease onset [, 14–1].
However, despite this, no other relationship be-
tween the NOD2 genotype and disease behavior
or response to treatment could be identified so far
– and there is no hope that there will be more def-
inite relationships and associations identified in
the future. Thus, the clinical impact of knowing
the patient’s genotype is limited so far. Screening
for NOD2/CARD15 mutations in order to iden-
tify high-risk individuals or to introduce an indi-
vidualised disease management is therefore cur-
rently not recommended.
Many patients ask whether a genetic screen-
ing could not quantify the risk to develop CD in
their children. The relative risk to develop CD is
increased by a factor of 4–5, if NOD2/CARD15
variants are present. On the other hand, as previ-
ously mentioned, more than 10% of the healthy
population carry NOD2/CARD15 variants. This
already indicates that the absolute risk (which is
the only important number) must be low: it in-
creases from 0.1% to 0.4% if NOD2/CARD15
variants are present. Such numbers are not help-
ful for individual risk predictions – especially as
there is no preventive treatment available.
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What was learnt from the analysis of NOD2/CARD15 variants
on CD pathogenesis?
The function of NOD2/CARD15 has been
investigated in detail (see figure 1). NOD2/
CARD15 was the first genetic base for stratifying
disease phenotype locations and is associated with
small intestinal involvement [18]. The most im-
portant information may be that it is an intracel-
lular “alarm button”, a receptor recognising in-
vading bacteria, that entered the mucosal wall.
Muramyl dipeptide (MurNAc-L-Ala-D-isoGln,
MDP), a component of the bacterial wall derived
from peptidoglycan as the essential structure in
bacteria, was found to be the major ligand for
NOD2 [19, 20]. MDP is a component of the wall
of Gram-positive bacteria. MDP is actively trans-
ported into epithelial cells via hPepT1, a brush-
border transporter expressed in the small intestine
[21, 22] or it might be taken up via currently un-
known mechanisms. NOD2 mutants associated
with susceptibility to CD seem to be deficient in
their recognition of MDP [20]. Interestingly,
MDP was long known to be the essential struc-
ture in Freund’s adjuvans, important for vaccina-
tion success.
As NOD2/CARD15 confers the risk to de-
velop CD in one third of patients, the question of
which cells of the intestinal mucosa express
NOD2/CARD15 was synonymous with the ques-
tion of which cells are most relevant for the
pathogenesis of the disease in those patients. Sur-
prisingly expression was not found in those cells
which are usually targeted with treatments, the
central player of adaptive immunity: the T-lym-
phocytes (azathioprine, 6-mercaptopurine or
methotrexate mainly act on T-cells). In contrast,
NOD2/CARD15 protein expression was mainly
found in the central cell component of the innate
immune system, a cell type capable to phagocy-
tose (eat and destroy) pathogens, to react to bacte-
ria by secreting cytokines and toxic oxygen rad-
icals: macrophages in the normal colon displayed
the most prominent NOD2/CARD15 protein ex-
pression [23]. This surprising finding (which
changed the view of IBD as a “T-cell disease”) was
even “topped” by the results on NOD2/CARD15
protein expression in inflamed mucosa from CD
patients. Again no expression in T-cells could be
detected, however, increased NOD2/CARD15
expression was found in intestinal epithelial cells
(IECs) and again macrophages in CD lesions [23–
26]. A role for the epithelial Paneth cells in
NOD2/CARD15 related IBD pathophysiology is
supported by data showing NOD2/CARD15
mRNA enriched in crypts compared with villi,
with Paneth cells being the most prominent cells
expressing NOD2/CARD15 in normal and CD-
mucosa [26–28]. Colonic epithelial cells also have
been shown to express this protein, however, to
lower mRNA levels as compared to Paneth cells
or intestinal macrophages [25, 29, 30]. These data
indicated that changes found in the “intestinal im-
mune system” targeted by most therapies avail-
able so far are secondary. At least CD is not a
“normal autoimmune disease” in which primarily
T-cells are misdirected against “self-structures”. It
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may even be assumed that the adaptive immune
system does exactly what it is supposed to do.
However, it receives misleading orders from a dis-
turbed system of primary defense: the innate im-
mune system, in the case of the intestinal mucosa
consisting of the primary barrier forming epithe-
lial cells and the intestinal macrophages. These
exciting new insights can only be described as a
change in the basic paradigm of IBD pathophysi-
ology. They have changed the focus of big drug
companies in their search for new therapeutic op-
tions for IBD, and this latter fact will certainly in-
fluence the upcoming therapeutic options for fu-
ture treatment of IBD patients.
SWISS MeD Wkly 20 09 ; 139 ( 37–38 ) : 527–534 · www.smw.ch
Figure 1
Pathophysiology of IBD: Barrier function
and innate immune defense against invading
pathogens are altered in CD.
After active uptake via peptide transporter
hPepT1 or other mechanisms, peptidoglycans
are taken up and degraded by the endo-lyso-
some. Variants of endolysolomal proteins (such
as ATG16l1) have been shown to be associated
with susceptibility to develop CD. MDP binds to
the NOD2/CARD15 protein thereby activating
NFκB and consequently inducingTNF, Il-1, Il-6,
and Il-8 secretion. NOD2 variants are less effec-
tive in binding MDP and do not activate the in-
nate immune systems as effective as wildtype
NOD2. In summary, the genetic variants asso-
ciated with an increased risk to develop CD
cause a less effective reaction to invading bac-
teria and bacterial products.
What is the normal function of NOD2/CARD15 and how is it changed
during CD pathogenesis?
NOD2/CARD15 is a member of a super-
family of genes, the NBS-LRR proteins (for nu-
cleotide-binding site and leucine-rich repeat),
which are involved in intracellular recognition of
microbes and their products [31]. NBS-LRR pro-
teins are characterised by a C-terminal leucine-
rich repeat (LRR) domain able to bind microbial
motifs, an intermediary nucleotide binding site
(NBS) essential for the oligomerization and signal
transduction, and a caspase-activating and recruit-
ment domain (CARD).
NBS-LRR proteins play an important role
in the innate immune system. The family also
includes such proteins as the so-called Nalp mole-
cules. These proteins are involved in inflamma-
tory responses and a number of auto-immune
diseases are related to mutations in these family
members [32]. There is a second class of “detec-
tion molecules” for bacterial and viral products,
which are named toll like receptors (TLRs). Both
classes of microbial product sensors are classified
as “pattern recognition receptors” (PRRs). After
being activated by the presence of microbial
ligands they usually initiate a defense response.
The microbial ligands of PRRs have been termed
“pathogen-associated molecular patterns”
(PAMPs), however, not all molecules detected are
always pathogenic. For example, bacterial or viral
DNA motifs bound by TLR9 may induce amelio-
ration of colitis as well as aggravation depending
on the circumstances [33–35].
The microbial patterns recognised by PRRs
are evolutionary highly conserved. Plants already
have an innate immune system of PRRs recognis-
ing the same patterns of microbes as compared to
humans. This indicates several important points:
i) the innate immune system has been developed
very early in evolution and obviously has been
very successful as it is highly conserved. ii) as it is
likely to be very important for self defense its ex-
pression is most relevant at sides of high antigen
and pathogen density, such as the intestinal mu-
cosa. iii) disturbances of these functions are likely
to cause diseases. As the function is very basic dif-
ferent alterations may finally lead to the same re-
action pattern: mucosal inflammation.
In summary, both classes of PRRs (NLRs and
TLRs) are involved in detecting potentially
harmful microbes through PAMP recognition
followed by the initiation of a defense reaction
and sometimes but not always inflammation with
activation of the adaptive immune system. De-
fense reactions beside activation of the adaptive
immune system may be the secretion of locally
acting antibacterial molecules such as oxygen rad-
icals [36].
NOD2/CARD15 induced signal transduction
is usually followed by NF-κB activation. Muta-
tions of the gene, as found in CD, are thought
to be associated with an impaired activation of
NF-κB.
MDP – NOD2/CARD15 interaction is fol-
lowed by activation of the innate immune system
reflected by an induction of α- and β-defensins
secretion as a first line of defense at the mucosal
barrier in response to a bacterial attack. Nod2
protein activation furthermore increases the pro-
duction of pro-inflammatory cytokines such as
TNFα, IL-1β or IL-8, which also reflects an early
defense mechanism [29, 3–39].
In epithelial cells MDP binding to NOD2 is
specifically followed by an induction of the
expression of the inducible antimicrobial peptide
hBD-2 [38]. The hBD-2 promoter contains puta-
tive binding sites for NF-κB providing an expla-
nation how NOD2 activation may induce hBD-2
transcription (fig. 2) [38]. Mutation of the two
proximal NF-κB sites in the hBD-2 promoter
region almost completely inhibits the MDP-
induced hBD-2 promoter activation in NOD2-
overexpressing cells [38].
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Nod2 variants are associated with reduced production of defensins
Analyses of CD Patients with wild type (wt)
Nod2 showed that the expression of human α-de-
fensin 5 (HD5) is approximately 50% reduced in
NOD2 variant subjects when compared to wt pa-
tients [40]. HD6 levels were similarly reduced. In
contrast no significant changes in most other
Paneth cell antibacterial factors were found, sug-
gesting a specific defect of α-defensin production
associated with NOD2 variants.
In a parallel study, the same group found in
general, normal levels of β-defensins in CD pa-
tients whereas there were increased levels of β-de-
fensins 2 and 3 in UC patients [41]. Therefore,
Wehkamp and colleagues suggested that in CD
there is also a lack of β-defensin induction and
thus a relative deficiency of this defensin con-
tributing to impaired barrier functions.
One of the first findings indicating a role of
Nod2 for intestinal barrier function was the dis-
covery that Nod2 is involved in the regulation of
in α-defensin expression. As previously men-
tioned, Nod2 is expressed in Paneth cells and pro-
tects epithelial cells from bacterial infection. Pa-
tients carrying the SNP13 variant (a frameshift
mutation at Leu100) were identified to exhibit
the most severe decrease in mucosal HD5 levels
when compared to Nod2 wt CD patients [40, 42].
Patients with CD, not carrying this mutation also
show a decrease of defensins, which is caused by
alteredWNT signalling (WNTTCF4) [43].
Nevertheless it is not unequivocally proven
that the reduction in defensin production and
subsequent deficiency in antibacterial activity
caused by Nod2 variants (or at least one of the
three major Nod2 variants) is a major factor in the
pathogenesis of CD. An impairment of mucosal
barrier function can itself be a cause of gut inflam-
mation. A chimeric mouse expressing a dominant-
negative N-cadherin transgene in the intestinal
epithelium, followed by leaky tight junctions be-
tween cells, developed severe mucosal inflamma-
tion [44].
As the detection of microbial antigens is a basic function of the mucosal
immune system: Is it only relevant for CD?
As mentioned above a disturbed innate im-
mune response is a very important and basic
mechanism of self defense and should not only be
relevant for CD. Therefore, it was only a short
time until the impact of the new insights into CD
pathogenesis for other diseases could be demon-
strated. One of the first fields in which a high im-
pact of NOD2 variants on disease development,
pathogenesis and even disease associated mortal-
ity could be demonstrated was graft versus host
disease (GvHD) after allogenic bone marrow
transplantation.
Individuals suffering from intestinal GvHD
after allogeneic bone marrow transplantation
(SCT) show histological features similar to CD.
GvHD is associated with increased intestinal per-
meability and could therefore also be a problem of a
defective intestinal barrier. It is still the most severe
complication following SCT. Experimental models
indicate the primacy of gastrointestinal damage:
Conditioning related damage of the in-testinal ep-
ithelium results in bacterial translocation followed
by increased cytokine release by macro-
phages/monocytes andT cell activation [45, 46].
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The incidence of severe GvHD (and assoc-
iated gastrointestinal GvHD) rose from 18% in
donor/recipient pairs without any NOD2/
CARD15 variant to 3% in pairs with either
donor or recipient mutations with a subsequent
increase of treatment related mortality (TRM)
from 33 to 60% [4–49]. In a subgroup of 11
donor/recipient pairs where both donor and re-
cipient had NOD2 variants, severe GvHD rose
from 22 to 55% and transplantation related mor-
tality rose from 38% to 100% [4–49].
A deficient antibacterial response with de-
creased ability to clear commensal bacteria in
both, IEC/paneth cells of the recipient’s mucosa
and donor monocytes might result in increased
bacterial translocation and subsequent mucosal in-
flammation in this case [42]. Assuming a compara-
ble pathophysiology in GvHD and CD, these data
again support the hypothesis that the primary
pathophysiology in a subgroup of CD patients is a
IEC- and monocyte/macrophage defect and that
alterations in T-cell function are secondary.
As the stem cell donors also seemed to have a
major impact, further conclusions can be drawn
for NOD2/CARD15 functions on the intestinal
barrier. A NOD2/CARD15 variant mediated
altered pathway of activation of intestinal
macrophages or antigen presenting cells (APCs)
might be an additional important mechanism that
could at least explain the strong association of
NOD2/CARD15 variants with GvHD.When the
causes of death in the investigated SCT-patient
cohorts were analyzed, GvHD and progressive
pulmonary failure resembling adult respiratory
distress syndrome were the major causes of death
in recipient/donor pairs with NOD2/CARD15
variants [4, 49]. As APCs express NOD2/
CARD15, the altered pathways of APC activation
might not only be relevant for the intestinal bar-
rier but also involve other organs forming a bar-
rier against the exterior, such as the lung.
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Other genetic polymorphism and alterations found to be involved
in the pathogenesis of CD
A number of other genetic polymorphisms
have been reported to play a role in IBD patho-
genesis. The human multidrug resistance 1
(MDR1) gene product P-glycoprotein is highly
expressed in intestinal epithelial cells and consti-
tutes a barrier against xenobiotics. Polymor-
phisms causing lower protein expression have
been associated with the risk to develop UC or
IBD in general [50, 51]. Therefore, P-glycopro-
tein could play a role in the defense against intes-
tinal bacteria [52].
In a genome-wide association study, 199
non-synonymous single nucleotide polymor-
phisms were investigated in 35 individuals with
CD and 368 controls [53]. The authors found a
disease association of rs2241880 in the au-
tophagy-related 16-like 1 gene (ATG16L1) which
could be replicated. The ATG16L1 gene encodes
a protein in the autophagosome pathway that
processes intracellular bacteria. The authors also
found a statistically significant interaction with re-
spect to CD risk between ATG16L1 and the
NOD2/CARD15 susceptibility variants [53]. This
gene and its protein product makes the autophagic
pathway an attractive therapeutic target and drug
companies have started developing treatment
strategies aimed at this gene. A second study
analysing the ATG16L1 gene in human and mouse
intestinal Paneth cells found very similar results,
potentially linking this gene to defensins [54].
A genome-wide association study of ileal
Crohn disease and two independent replication
studies identified strong and significantly repli-
cated associations with a coding variant in
ATG16L1 [55]. They also found strong associa-
tions of variations in the genomic regions encod-
ing PHOX2B, NCF4 and a predicted gene on
16q24.1 (FAM92B) [55]. The authors demon-
strated that ATG16L1 is expressed in intestinal
epithelial cell lines and that functional knockdown
of this gene abrogates autophagy of Salmonella
typhimurium. Again these results confirmed that
host cell responses to intracellular microbes (in-
volving autophagy) are crucial in the pathogenesis
of CD.
In a genome-wide association study of 3230
CD cases and 4829 controls (all of European de-
scent) the Welcome Trust consortium could con-
firm eleven associations previously replicated and
established at genome-wide significance levels in-
cluding NOD2, 5q31 (IBD5)15 as well as IL23R,
ATG16L1, IRGM, TNFSF15 and PTPN2 [56].
In addition 21 new loci could be replicated with
newly IBD associated genes such as PTPN22,
ITLN1, IL12B, CDKAL1, CCR6, JAK2, C11
or f30, MUC19 or STAT3 [56]. The function
of a number of those genes is currently unclear
and is still to be defined [5]. At this time the
identified variations explain only a fraction of IBD
burden in the population, suggesting that other
factors, such as interacting environmental
factors, are major contributors to disease suscepti-
bility [58].
Furthermore, a reduced gene copy number of
the β-defensin cluster on chromosome 8 results in
an attenuated induction of human β-defensin 2
(HBD2) and is associated with colonic involve-
ment of CD [59].
The genetic knowledge of IBD is increasing
and turns out to be a success story. As more candi-
date genes become available, it is likely that the
main gene variants predisposing to IBD will be
found. As a whole the published literature indi-
cates that Nod2 mediated NF-kappaB activation,
subsequent induction of anti-microbial peptides
such as defensins and the induction of cytokine
expression are essential for the function of the in-
testinal barrier and for the prevention of bacterial
translocation. The data indicate why a defect in
the induction of this acute defense response is as-
sociated with chronic inflammation, as invading
bacteria that cannot be readily detected and elim-
inated may start a backup mechanism of inflam-
mation, finally resulting in chronic inflammatory
reaction, followed by further impairment of the
mucosal barrier. These new insights in the patho-
physiology of CD will provide further under-
standing of concepts such as environmental influ-
ence, smoking, diet and intestinal flora in the
modulation of CD susceptibility. Hopefully, the
translation of genetics to clinical benefit will soon
become reality.
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“Let them eat dirt”: The role of bacteria and probiotics
With the finding, that most susceptibility
genes for CD are involved in innate immune
mechanisms and the primary defense against bacte-
ria entering the mucosa, for the first time a unifying
concept of the “genetic pathophysiology hypothe-
sis” and the “environment pathophysiology hy-
pothesis” of IBD was possible. Bacteria are the link
between environment and mucosal defense system.
However, evidence that bacteria play a major
role in the initiation and perpetuation of intestinal
inflammation has been obtained long ago in animal
studies with germ free maintained mouse models, a
condition under which these animals do not de-
velop intestinal inflammation in contrast to specific
pathogen free (SPF) kept rodents [60].
In colonic lesions of CD patients adherent-in-
vasive E. coli have been found. In addition an in-
creased bacterial translocation into deeper layers of
the mucosa has been described in CD patients,
which could be of pathophysiological relevance. E.
coli Nissle has been proven to be of therapeutic po-
tential in IBD [61–64].The mechanism could be an
inhibition of the adherence and invasion of patho-
genic E. coli [65], which further supports a role of
bacterial translocation into the mucosa in the
pathogenesis of CD. In fact fecal bacterial compo-
sition is altered in CD patients compared to
healthy persons [66].
A role for certain bacteria in the pathogenesis
of IBD is further supported by the positive effects
of probiotic bacteria on intestinal inflammation, se-
cretion of pro-inflammatory cytokines and induc-
tion of β-defensins [6–6]. An increased bacterial
invasion into the mucosa could be caused by inef-
fective innate responses such as mutated and defec-
tive NOD2. On the other hand impaired or defec-
tive protection mechanisms of the mucosa could be
involved.
A direct mucosal protection is mediated by
molecules such as mucins, trefoil peptides or de-
fensins. A deficiency in these molecules could cause
a breakdown of mucosal protection [3, 43, –80].
In humans, Swidsinski and co-workers demon-
strated that the intestinal mucosal surface beneath
the mucus layer is usually free of bacteria. In pa-
tients with CD orUC, the thickness of the mucosa-
protecting mucus layer is decreased. More impor-
tantly, bacterial adherence to the epithelial surface
could be demonstrated as well as epithelial tissue
defects and deep mucosal infiltration with bacteria
and leucocytes [81, 82]. The mucus above the ep-
ithelial cells is strongly colonised with bacteria in
biopsies from patients with ulcerative colitis and
Crohn’s disease when compared to controls [81 and
own unpublished data]. This indicates that the ep-
ithelial mucus layer normally prevents contact be-
tween luminal bacteria and epithelial cells. How-
ever, in contrast it indicates that IBD is associated
with breaks in the mucus barrier and colonisation
of the mucus with bacteria.
Those bacteria colonising the mucus may be
able to directly influence intestinal barrier integrity
[83–85].
Conclusion
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